Replimune Group Stock Price, News & Analysis

Replimune Group Inc. (NASDAQ: REPL) reported its financial results for the third fiscal quarter ended December 31, 2021, revealing a net loss of $29.7 million, up from $21.8 million a year ago. Research and development expenses rose to $19.4 million, reflecting heightened clinical activities. The company holds $420.2 million in cash, expected to fund operations until mid-2024. Upcoming milestones include initial data releases from various clinical trials and an investor event in March 2022 to discuss commercial strategies and RP2/3 development plans.

Replimune Group Inc. (NASDAQ: REPL) announced the resignation of Otello Stampacchia, Ph.D., from its Board of Directors effective January 31, 2022. Dr. Stampacchia, a co-leader of Replimune’s seed financing, has decided to focus on his commitments at Omega Funds. CEO Philip Astley-Sparke expressed gratitude for Dr. Stampacchia’s contributions to Replimune's growth from inception to a leader in oncolytic immunotherapies. Replimune aims to innovate cancer treatment through its proprietary RPx platform, enhancing both local and systemic therapeutic effects.

Replimune Group (Nasdaq: REPL) provided a corporate update on January 10, 2022, highlighting the progress of its clinical trials for RP1, RP2, and RP3. The CERPASS trial for RP1 in cutaneous squamous cell carcinoma (CSCC) is on track for enrollment completion mid-year, leading to primary data analysis later. Interim data from the IGNYTE trial, assessing RP1's efficacy in anti-PD1 failed melanoma, is expected by late 2022. Replimune aims to expand RP2 and RP3 trials into diverse cancer types, with detailed development plans to be unveiled in Q1 2022.

Replimune Group, a clinical-stage biotechnology firm, has announced that its CEO, Philip Astley-Sparke, will present on January 10, 2022, at the 40th Annual J.P. Morgan Healthcare Conference. The event will be held virtually at 7:30 AM ET. A webcast will be accessible through Replimune’s website, with a replay available for 30 days. Founded in 2015, Replimune focuses on tumor-directed oncolytic immunotherapies, utilizing its proprietary RPx platform to enhance cancer treatment.

Replimune Group, Inc. (Nasdaq: REPL) has appointed Christy Oliger to its Board of Directors effective December 1, 2021. Oliger brings nearly 30 years of pharmaceutical and biotechnology experience, particularly in oncology, having previously held key roles at Genentech. CEO Philip Astley-Sparke expressed optimism about Oliger's contributions to the company’s leading pipeline of oncolytic immunotherapies. Replimune focuses on advancing its innovative immuno-gene therapy platform aimed at enhancing cancer treatment.

Replimune Group (Nasdaq: REPL) announced updated interim data from its Phase 1 trial of RP2, demonstrating strong responses in difficult-to-treat cancers. The trial includes both RP2 as a monotherapy and in combination with Opdivo. Notable findings include durable responses in patients with esophageal and mucoepidermoid carcinoma lasting 19-22 months. The 30-patient cohort with Opdivo showed a 23.3% partial response rate, with ongoing responses exceeding 425 days. The company plans to enroll an additional 24 patients with liver metastases in response to positive results.

Replimune Group (NASDAQ: REPL) reported a net loss of $29.4 million for Q2 2021, up from $20.1 million in Q2 2020. R&D expenses increased to $19.9 million, driven by expanded clinical programs. The company maintains a strong cash position of approximately $436 million, expected to fund operations into H2 2024. Full patient accrual in the CERPASS trial is anticipated by mid-2022, with primary data trigger expected by late 2022. Initial data from the IGNYTE trial is also set for late 2022, reinforcing Replimune's focus on establishing a robust skin cancer franchise.

Replimune Group, Inc. (NASDAQ: REPL) announced upcoming presentations at two key conferences. The first, BMO Biopharma Spotlight Series, occurs on November 8, 2021, focusing on next-gen oncolytic virus therapies. The second event, Piper Sandler 33rd Virtual Annual Healthcare Conference, runs from November 30 to December 2, 2021, featuring a pre-recorded fireside chat available on-demand starting November 22. Replimune develops innovative oncolytic immuno-gene therapies using its Immulytic® platform to enhance cancer treatment.

Replimune Group, Inc. (Nasdaq: REPL) announced four poster presentations at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. Key presentations include:

• RP2: Phase 1 trial with nivolumab for advanced solid tumors.
• ARTACUS: Phase 1b/2 study on RP1 in transplant recipients.
• CERPASS: Phase 2 study of cemiplimab ± RP1 for advanced squamous cell carcinoma.
• IGNYTE: Phase 1/2 trial of RP1 ± nivolumab in advanced tumors.

Full posters will be available on Replimune's website.